Your browser doesn't support javascript.
loading
Modeling YAP fusions: a paradigm for investigating rare cancers?
Sahebjam, Solmaz; Gilbert, Mark R.
  • Sahebjam S; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
  • Gilbert MR; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
Genes Dev ; 36(15-16): 874-875, 2022 08 01.
Article en En | MEDLINE | ID: mdl-36207139
ABSTRACT
Loss of the NF2 tumor suppressor gene is a common finding in meningiomas, and more recently YAP1 fusions have been found in a subset of pediatric NF2 wild-type meningiomas. In the previous issue of Genes & Development, Szulzewsky and colleagues (pp. 857-870) showed that TEAD-dependent YAP1 activity by either the loss of the NF2 gene or YAP1-MAML2 fusion is an oncogenic process promoting meningioma tumorigenesis. Furthermore, pharmacological inhibition of YAP1-TEAD resulted in antitumor activity in both YAP1 fusion-positive and NF2 mutant meningiomas. Together, these data indicate that disruption of the YAP1-TEAD interaction raises a potential therapeutic option for these tumors that requires future investigation.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Factores de Transcripción / Proteínas de Ciclo Celular / Neoplasias Meníngeas / Meningioma Tipo de estudio: Prognostic_studies Límite: Child / Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Factores de Transcripción / Proteínas de Ciclo Celular / Neoplasias Meníngeas / Meningioma Tipo de estudio: Prognostic_studies Límite: Child / Humans Idioma: En Año: 2022 Tipo del documento: Article